News & Updates
Filter by Specialty:
MRNA booster shot durably bolsters defenses against severe COVID-19
Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.
MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022Ivermectin not superior to placebo in mild COVID-19
Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.
Ivermectin not superior to placebo in mild COVID-19
13 Sep 2022Nirmatrelvir conferred protection in older adults during the Omicron outbreak
During the surge of the Omicron (B.1.1.529) variant, antiviral therapy with nirmatrelvir significantly reduced the rate of COVID-19-related hospitalization or death among patients aged ≥65 years, according to a recent study.
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
13 Sep 20223D-printed masks a good alternative to N95 respirators
Reusable 3D-printed respirators offer a cost-effective alternative to N95 masks in providing protection against respiratory pathogens, such as SARS-CoV-2, suggests a recent study. In addition, fit testing results show that some 3D-printed mask designs appear to exceed the fit of N95 masks.
3D-printed masks a good alternative to N95 respirators
12 Sep 2022COVID-19 lockdown weakens metabolism in people with glucose intolerance
In Japan, the declaration of a state of emergency in response to the COVID-19 pandemic led to negative metabolic consequences in people with glucose intolerance, such as lowered skeletal muscle and increased body weight and body fat, a recent study has found.
COVID-19 lockdown weakens metabolism in people with glucose intolerance
10 Sep 2022IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.